Skip to main content

Alex Lobo

Head of Investor Relations

Alaunos Therapeutics, Inc. (TCRT)

Analyst

Former Speaker

Head of Investor Relations

Inhibikase Therapeutics, Inc. (IKT)

Equibles does not estimate personal net worth.

Get an email with a short summary when Alaunos Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get TCRT alerts

About Alex Lobo

Alex Lobo is recorded as Head of Investor Relations at Alaunos Therapeutics, Inc. (TCRT), Analyst at Former Speaker and Head of Investor Relations at Inhibikase Therapeutics, Inc. (IKT). Alex Lobo has spoken on 7 earnings calls across 2 companies, most recently for Inhibikase Therapeutics, Inc. on December 31, 2023. Those appearances were for Inhibikase Therapeutics, Inc. (IKT) and Alaunos Therapeutics, Inc. (TCRT). Inhibikase Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Alaunos Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inhibikase Therapeutics, Inc. includes Mark Iwicki (CEO and Board Member), Amit Munshi (Chairman and Board Member), Roberto Bellini (Chairman and Board Member) and 5 others.

Alex Lobo on recent calls

“Good morning, and welcome to Inhibikase Therapeutics fourth quarter and full year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.”
Head of Investor Relations, Inhibikase Therapeutics, Inc. Q4 FY2023 Earnings Call ·
“Good morning, and welcome to the Inhibikase Therapeutics Second Quarter 2023 Financial Results Conference Call and Audio Webcast. With me today is Dr. Milton Werner, Chief Executive Officer; Joseph Frattaroli, Chief Financial Officer.”
Head of Investor Relations, Inhibikase Therapeutics, Inc. Q2 FY2023 Earnings Call ·
“With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer. On Monday, May 15, 2023, Inhibikase issued a press release announcing financial results for the first quarter ended March 31, 2023.”
Head of Investor Relations, Inhibikase Therapeutics, Inc. Q1 FY2023 Earnings Call ·
“Good morning, and welcome to Inhibikase Therapeutics third quarter 2022 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer.”
Head of Investor Relations, Inhibikase Therapeutics, Inc. Q3 FY2022 Earnings Call ·
“And welcome to the Alaunos Therapeutics third quarter 2022 financial results conference call and audio webcast. Please note that today’s webcast contains slides, which are available through the audio webcasting platform.”
Head of Investor Relations, Alaunos Therapeutics, Inc. Q3 FY2022 Earnings Call ·

Affiliation history

Company network

Leadership on record at Inhibikase Therapeutics, Inc.

Leadership on record at Alaunos Therapeutics, Inc.

Recent activity